Carisma Therapeutics (CARM) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

CARM Carisma Therapeutics

Watchlist

0.418
-0.024-5.35%

Close Dec 20 16:00 ET

0.426
+0.009+2.03%

Post 20:05 ET

17.45MMarket Cap-0.27P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

H.C. Wainwright Downgrades Carisma Therapeutics(CARM.US) to Hold Rating
Moomoo NewsDec 16 07:31 ET · Ratings
Express News | HC Wainwright & Co. Downgrades CARISMA Therapeutics to Neutral
BenzingaDec 16 07:24 ET
Carisma Downgraded by Baird Over Lack of Near-term Catalysts
Seeking AlphaDec 12 16:26 ET
Express News | D. Boral Capital Maintains Buy on CARISMA Therapeutics, Maintains $12 Price Target
BenzingaDec 12 14:42 ET
Carisma Therapeutics Price Target Cut to $1.00/Share From $10.00 by Baird
Dow JonesDec 12 06:00 ET · Ratings
Baird Downgrades Carisma Therapeutics(CARM.US) to Hold Rating, Cuts Target Price to $1
Moomoo NewsDec 12 05:32 ET · Ratings

Comments

Ant-waan

Dec 17 15:11

$Carisma Therapeutics (CARM.US)$
in progress 😎

Share Your Profit/Loss

Ant-waan

Dec 17 13:27

$Carisma Therapeutics (CARM.US)$ park sum money here 😎

Jaguar8

Dec 9 07:34

NEWS

$Carisma Therapeutics (CARM.US)$
Carisma Therapeutics Announces Strategic Restructuring to Re-prioritize Pipeline
Monday, 9th December at 8:30 am
Resources realigned to focus primarily on in vivo macrophage engineering platform for fibrosis, oncology and autoimmune disease therapies
Development of CT-0525 to be discontinued; workforce reduced by 34%
PHILADELPHIA, Dec. 9, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a leader in macrophage-focused ...

Stock_Drift

Nov 17 16:25

11/18/24 watchlist 🚨🚨🚨🚨🚨 *not trading advice*

$Simpple (SPPL.US)$ $AtlasClear (ATCH.US)$ $DDC Enterprise (DDC.US)$ $Mercurity Fintech (MFH.US)$ $Pulmatrix (PULM.US)$ $Carisma Therapeutics (CARM.US)$

Jaguar8

Nov 17 14:54

NEWS

$Carisma Therapeutics (CARM.US)$
Carisma Therapeutics Presents Promising New Preclinical Data on Engineered Macrophages for the Treatment of Liver Fibrosis at AASLD The Liver Meeting® 2024
Carisma Therapeutics (NASDAQ: CARM) presented promising preclinical data on engineered macrophages for treating liver fibrosis at AASLD The Liver Meeting® 2024. The research shows that macrophages can be genetically engineered to target specific pathways in liver disease using factors like TIM4, relaxin, an...

Heat List

Overall

No Data